Devyantram creates bio‑hybrid robotic platforms that integrate engineered muscle tissue, nanowire‑based neural interfaces, and edge AI controllers into a closed‑loop system for real‑time biochemical interaction. The modular hardware and ROS‑2‑compatible software stack enable programmable nanobot swarms and shape‑shifting humanoid robots for intracellular therapy, autonomous environmental remediation, and adaptive defense operations.
Funding
Funding not disclosed
Founders
Product
Problem
Current robotic platforms treat intelligence as a detached software layer, which limits their ability to adapt to complex biological or environmental contexts. This separation prevents machines from performing tasks that require real‑time biochemical interaction, such as intracellular therapy, pollutant degradation, or dynamic battlefield decision‑making.
Solution
Devyantram delivers bio‑hybrid robots that embed living tissue, engineered nanostructures, and artificial‑intelligence controllers into a unified control loop. At the nanoscale, self‑propelling nanobots carry synthetic enzymes or gene‑editing payloads to target cells, while microrobots coordinate swarm behaviors for large‑area remediation. At the macro scale, shape‑shifting humanoid platforms integrate bio‑fabricated muscle fibers and nanowire‑based neural interfaces, enabling on‑board organic computation that continuously grounds AI decisions in physiological feedback. The platform provides a modular software stack for edge AI inference, secure OTA updates, and API‑driven integration with enterprise systems, allowing customers to deploy adaptive machines across medical, environmental, and defense domains without extensive custom engineering.
Target Audience
Primary customers are hospitals and biotech firms seeking intracellular therapeutic robots, environmental service companies requiring autonomous remediation swarms, and defense contractors that need adaptive humanoid platforms for reconnaissance and logistics. Additional adopters include advanced manufacturing integrators and smart‑home solution providers.
Features
- Bio‑fabricated actuation layers combining engineered muscle tissue with nanowire‑embedded synthetic neurons for low‑latency, energy‑efficient motion control
- Integrated nanobot swarm architecture with programmable chemotaxis, on‑board power harvesting, and biodegradable chassis for in‑vivo drug delivery and pollutant breakdown
- Closed‑loop bio‑feedback loop that fuses electrophysiological signals, metabolic markers, and sensor data into real‑time AI inference at the edge
- Polymorphic chassis using shape‑memory alloys and modular nanocomposite panels, enabling autonomous reconfiguration for task‑specific morphology
- Secure, blockchain‑anchored firmware distribution and OTA update framework compliant with FDA 21 CFR Part 820 and MIL‑STD‑810 standards
- Scalable SDK with ROS‑2 compatible drivers, allowing rapid integration of custom AI models, sensor suites, and enterprise data pipelines
- Licensing‑ready API exposing synthetic cognition metrics (e.g., neural activity maps, adaptive reasoning scores) for downstream analytics and compliance reporting